

## OPTIGEN BLIC

## **Test Report**

Margit Rietman Nieuwstraat 5 Enkhuizen, 1601 JJ Netherlands Optigen Accession #: 15-2170

VHL#: 84994

Report issued for: Puck

## OptiGen Test Certificate

Optigen Accession #: 15-2170

Test Performed: CEA/CH test

Registered Name: Daintree's Dutch Canadian Puck

Breed: Nova Scotia Duck Tolling Retriever

Sex: Male

Date of Birth: March 29, 2014

Owner(s):

Margit Rietman

Paul Veen

Test Completed: 03/18/2015 Report Issued: 03/18/2015

Result: Carrier

Sample Type: DNA - Blood

Reg#: 2987475

ID#: 5T 5B LF / 900026000531290

OPTIGEN

OptiGen Authorized Signature

www.optigen.com

Test Results: Genotype of your dog is CARRIER.
Risk for developing Collie Eye Anomaly/Choroidal Hypoplasia (CEA/CH): This dog will never develop CEA/CH.
Significance for breeding: This dog should only be bred to a mate of normal CEA/CH genotype in order to avoid producing pups affected with CEA/CH.

This interpretation is based on the test result of the DNA test for the specific mutation identified as causing CEA/CH in Nova Scotia Duck Tolling Retrievers as of the date on this report.

For further information, please consult the OptiGen website at www.optigen.com. Note: The use of this test is patent protected and licensed to OptiGen. See http://www.optigen.com/opt9\_patent.html for details.

International DNA Based Genetic Database: To register this result with OFA, make a copy, sign below, mail WITH FEE, to OFA, 2300 E. Nifong Blvd, Columbia, MO 65201-3856 or FAX to 573-875-5073, www.offa.org

I hereby certify that the sample submitted was of the animal described on this application. I authorize the OFA to release all information on the test results thus placing the results in the public domain and I hereby release OFA from any and all liability associated with the release of test information.

Signature of owner or authorized representative:

Cornell Business & Technology Park

tel: 607.257.0301

fax: 607.257.0353

767 Warren Road, Suite 300, Ithaca, NY 14850

email: genetest@optigen.com

web: www.optigen.com